2020
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal Of Clinical Oncology 2020, 38: 4317-4345. PMID: 33197225, DOI: 10.1200/jco.20.02672.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaFirst-line treatmentSecond-line therapyChild-Pugh classFirst-line therapyHepatocellular carcinomaSystemic therapyLiver diseaseTherapy optionsEastern Cooperative Oncology Group performance status 0Evidence-based clinical practice guidelinesSecond-line therapy optionsTyrosine kinase inhibitor sorafenibECOG PS 0Performance status 0Third-line therapyPhase IIIClinical practice guidelinesKinase inhibitor sorafenibTyrosine kinase inhibitorsAppropriate candidatesStatus 0ASCO guidelinesMost patientsPS 0
2019
Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies
Saffo S, Taddei TH. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Digestive Diseases And Sciences 2019, 64: 1016-1029. PMID: 30887150, DOI: 10.1007/s10620-019-05582-x.BooksConceptsAdvanced hepatocellular carcinomaHepatocellular carcinomaTreatment strategiesMulti-targeted tyrosine kinase inhibitorSystemic managementGeneral host factorsEffective systemic therapyInitial treatment strategyMulti-modal therapyOverall tumor burdenCancer-related deathNovel treatment strategiesTyrosine kinase inhibitorsDifferent treatment classesKey molecular targetsInoperable diseaseCheckpoint inhibitorsEmerging TherapiesMost patientsDurable cureSystemic therapyLandmark trialsTumor burdenTelomerase reverse transcriptaseTherapy
2018
Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching
Kaplan DE, Mehta R, D'Addeo K, Gade TP, Taddei TH. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. Journal Of Vascular And Interventional Radiology 2018, 29: 540-549.e4. PMID: 29477619, PMCID: PMC6104514, DOI: 10.1016/j.jvir.2017.11.033.Peer-Reviewed Original ResearchConceptsUnresectable hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaMacrovascular invasionPropensity matchingOverall survivalEnd-stage liver disease (MELD) scoreBarcelona Clinic Liver Cancer stageVeterans Health Administration hospitalsInitiation of sorafenibSignificant hepatic dysfunctionLiver Disease scoreRetrospective cohort studyAdjuvant transarterial chemoembolizationLiver Cancer stageMulti-institutional studySorafenib initiationHepatic dysfunctionCohort studyMost patientsSystemic therapyPrimary outcomeUnadjusted analysesMultimodal therapySubgroup analysis